Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 10 of 5804
-
Immunotherapy after kidney surgery may delay cancer return in rare kidney cancer
Disease control Not yet recruitingThis phase III trial compares the effect of pembrolizumab to active surveillance after a surgical procedure to completely or partially remove a kidney (nephrectomy) in improving time without disease in patients with non-clear cell renal cell cancer. Immunotherapy with monoclonal …
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Could a second dose of dengue vaccine boost protection for kids?
⭐️ VACCINE ⭐️ Not yet recruitingThis randomized, double-blind, three parallel-group, multicenter, phase 3b trial evaluates the safety and immunogenicity of Butantan-DV. The study compares two primary immunization regimens (Butantan-DV/Butantan-DV vs. Butantan-DV/Placebo) across both the 2-11 and 12-17 age cohor…
Phase: PHASE3 • Sponsor: Butantan Institute • Aim: ⭐️ VACCINE ⭐️
Last updated Jul 22, 2026 00:00 UTC
-
Brain stem cell transplant aims to restore movement after stroke
Disease control Not yet recruitingThe suNR1se II Study is a Phase 2b randomized, controlled, multi-center clinical trial evaluating the efficacy and safety of stereotactic intracerebral administration of CC-101 (f/k/a NR1), an investigational allogeneic neural stem cell therapy, in adults with chronic ischemic st…
Phase: PHASE2 • Sponsor: Clarion Cells, Inc. • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Could a pill stop snake venom? new trial tests oral drugs against antivenom
Disease control Not yet recruitingBites by venomous snakes can cause disability and can be life-threatening. We are doing research in adult patients to try and find medications that can be administered orally and can help to reduce disability and death due to snakebite. We do not know whether the drugs in this st…
Phase: PHASE2 • Sponsor: Liverpool School of Tropical Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Could a single pill after sex stop STIs in women?
Prevention Not yet recruitingThe bacterial sexually transmitted infections (STIs) chlamydia, gonorrhea, and syphilis cause multiple adverse outcomes in women, and prevention strategies are critically needed. This project will determine the efficacy of doxycycline post-exposure prophylaxis (doxy PEP) to preve…
Phase: PHASE4 • Sponsor: Tulane University • Aim: Prevention
Last updated Jul 17, 2026 00:00 UTC
-
New drug combo aims to keep lung cancer at bay longer
Disease control Not yet recruitingEligible participants with limited stage-small cell lung cancer (LS-SCLC) will be enrolled after completion of chemotherapy and radiation. Participants will be randomized to either tarlatamab in combination with durvalumab or durvalumab alone as consolidation therapy. Treatment w…
Phase: PHASE3 • Sponsor: PrECOG, LLC. • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Antibody boost may help infants suppress HIV faster
Disease control Not yet recruitingThe goal of this clinical trial is to learn if subcutaneous ePGT121v1-LS and VRC07-523-LS added to standard antiretroviral therapy (ART) is safe and helps improve HIV viral suppression in infants living with HIV in Mozambique and Cameroon. The study will also learn how the body p…
Phase: PHASE1, PHASE2 • Sponsor: Hospital Universitario 12 de Octubre • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Two-Drug combo aims to wipe out rectal cancer before surgery
Disease control Not yet recruitingThis is a randomized, controlled clinical trial based on prior exploratory findings, designed to evaluate the efficacy and safety of neoadjuvant chemoradiotherapy combined with tafolecimab(an anti-PCSK9 inhibitor) and sintilimab (an anti-PD-1 inhibitor) versus neoadjuvant chemora…
Phase: PHASE3 • Sponsor: Guangdong Provincial People's Hospital • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New pill shows promise in brain cancer fight
Disease control Not yet recruitingThe purpose of this clinical trial is to evaluate the addition of NG101m adjuvant therapy to standard of care treatment of glioblastoma multiforme. All subjects will receive NG101m capsules along with the standard treatment of temozolomide and radiation.
Phase: PHASE1, PHASE2 • Sponsor: NeuGATE Theranostics • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Triple-Drug cocktail aims to tame untreated CLL
Disease control Not yet recruitingThe goal of this clinical research study is to learn if the combination of zanubrutinib, sonrotoclax, and obinutuzumab can help to control previously untreated CLL/SLL.
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Dual-Pronged CAR T-Cell therapy takes aim at Hard-to-Treat leukemia
Disease control Not yet recruitingThe goal of this clinical research study is to find the recommended dose of KITE-753 in patients with relapsed/refractory B-cell ALL. The safety of KITE-753 will also be studied.
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Engineered immune cells take on aggressive lymphomas in new trial
Disease control Not yet recruitingThis clinical research study is to learn if CD70.CAR NK cell therapy can help to control early relapsed or primary refractory DLBCL and cHL.
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
New hope for hodgkin lymphoma: drug combo could replace chemo in relapsed patients
Disease control Not yet recruitingThis phase II trial compares the impact of brentuximab vedotin and nivolumab after radiation to standard of care high dose chemotherapy (HDT)-autologous stem cell transplant (ASCT) in standard-risk patients with classic Hodgkin lymphoma that has come back after a period of improv…
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New combo aims to outdo standard chemo for FLT3-Mutated leukemia
Disease control Not yet recruitingThis international, multicenter, randomized (1:1), open-label phase II/III trial will evaluate the efficacy and safety of gilteritinib combined with azacitidine and venetoclax (experimental arm) versus standard "7+3" induction plus a FLT3inhibitor (quizartinib or midostaurin) (co…
Phase: PHASE2, PHASE3 • Sponsor: European Organisation for Research and Treatment of Cancer - EORTC • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Can a Patient's own immune cells be supercharged to fight ovarian cancer?
⭐️ CURE ⭐️ Not yet recruitingPatients with recurrent ovarian cancer will undergo resection of a safely accessible metastatic lesion, from which tumor-infiltrating lymphocytes (TIL) will be cultured, metabolically reprogrammed for metabolic fit T cells, then selected for CD137+ activated T cells, and then exp…
Phase: PHASE2 • Sponsor: Medical University of South Carolina • Aim: ⭐️ CURE ⭐️
Last updated Jul 24, 2026 00:00 UTC
-
Gene therapy skin graft aims to heal wounds in 'Butterfly Children'
Disease control Not yet recruitingThe Master Protocol includes 3 studies (Study A, Study B, and Study C) that will evaluate pz-cel and related processes in the post-marketing setting. Study A investigates the efficacy and safety of non-conforming pz-cel in patients with Recessive Dystrophic Epidermolysis Bullosa…
Phase: PHASE4 • Sponsor: Abeona Therapeutics, Inc • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
New brain cancer wafer shows promise in recurrent glioblastoma trial
Disease control Not yet recruitingThis study is designed as a multi-center, randomized, open-label trial to evaluate the efficacy of Cerebraca Wafer in patients with recurrent glioblastoma. Cerebraca Wafer is intended for use in recurrent glioblastoma as an adjunct to surgery (followed by standard-of-care temozol…
Phase: PHASE2, PHASE3 • Sponsor: Everfront Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Can a Macrophage-Targeting drug supercharge CAR-T therapy?
Disease control Not yet recruitingAxatilimab + CAR-T in High-Risk Lymphoma
Phase: PHASE1 • Sponsor: Northside Hospital, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Could chemo plus immunotherapy double the punch against tough lung cancers?
Disease control Not yet recruitingAIO-TRK/YMO-0425 (High Five) is a phase III, open-label randomized-controlled, multicenter study to evaluate the progression-free survival by the addition of platinum-based chemotherapy to immunotherapy (IO) compared to IO monotherapy in patients with PD-L1high mNSCLC featuring a…
Phase: PHASE3 • Sponsor: AIO-Studien-gGmbH • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Can CBD tame seizures in severe childhood epilepsy? a major trial aims to find out
Disease control Not yet recruitingThe efficacy, safety, and tolerability of CBD-OS have been evaluated for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), and Tuberous sclerosis complex (TSC). The current JZP926-303 study is being conducted to evaluate the safety and…
Phase: PHASE3 • Sponsor: Jazz Pharmaceuticals • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC